| |||||||||
Type Congenic; Mutant Strain; Targeted Mutation; Additional information on Genetically Engineered Mutant Mice. Species laboratory mouse Donating Investigator Brian Kobilka, Stanford University Description
Mice that are homozygous for the targeted mutation are viable, normal in size and do not display any gross physical or behavioral abnormalities. Expression of the receptor in the brain was significantly reduced as assessed by antagonist binding, which indicated a 90% reduction. The antagonist binding assay is not entirely specific for the receptor, as the residual 10% binding was attributable to a different subtype of receptor. Mutant mice exhibit a resting tachycardia of more than 180 beats/min greater than normal. Although mutant mice do not have elevated blood pressure, administration of the hypotensive agonist, dexmedetomidine, does not reduce blood pressure. Electrical stimulation of isolated heart atria at frequencies mimicking physiological sympathetic nerve activity results in increased release of noradrenaline at high frequencies and inhibited release at low frequencies. Noradrenaline release from isolated wildtype atria is higher at high frequencies than at low frequencies. Inhibition of neurogenic contraction response to electrical stimulation in isolated vas deferens by dexmedetomidine is reduced in the mutant.Development
A targeting vector containing neomycin resistance gene driven by the mouse phosphoglycerate kinase promoter and herpes simplex virus thymidine kinase gene was used to disrupt the sequence of the targeted gene encoding the third transmembrane domain. The construct was electroporated into 129X1/SvJ x 129S1/Sv derived R1 embryonic stem (ES) cells. Correctly targeted ES cells were aggregated with 8-cell FVB/N morulae. The resulting chimeric animals were backcrossed to C57BL/6 mice.
Strains carrying other alleles of Adra2a
002777 B6.129S2-Adra2atm1Lel/J View Strains carrying other alleles of Adra2a (1 strain)
Congenic Nomenclature
View Mammalian Phenotype Terms
Mammalian Phenotype Terms
assigned by genotype
The following phenotype information may relate to a genetic background differing from this JAX® Mice strain.
Adra2atm1Bkk/Adra2atm1Bkk
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
- cardiovascular system phenotype
- abnormal blood pressure (MGI Ref ID J:76317)
- unlike wild-type controls, administration of the hypotensive agonist, dexmedetomidine, did not reduce blood pressure
- increased heart rate (MGI Ref ID J:76317)
- resting heart rate more than 180 beats/min greater than normal
- nervous system phenotype
- abnormal synaptic norepinephrine release (MGI Ref ID J:58591)
- increased release at high frequency electrical stimulation
- decreased release at low frequency electrical stimulation
Adra2atm1Bkk/Adra2atm1Bkk
involves: 129S1/Sv * 129X1/SvJView Research Applications
Research Applications
This mouse can be used to support research in many areas including:Adra2atm1Bkk related
Cardiovascular Research
Heart Abnormalities (tachycardia)
Hypotension
Neurobiology Research
Epilepsy
| Allele Symbol | Adra2atm1Bkk | ||
|---|---|---|---|
| Allele Name | targeted mutation 1, Brian K Kobilka | ||
| Allele Type | Targeted (knock-out) | ||
| Common Name(s) | alpha2A-; alpha2A-AR-; alpha2A-ARKO; alpha2A-KO; | ||
| Mutation Made By | Brian Kobilka, Stanford University | ||
| Strain of Origin | (129X1/SvJ x 129S1/Sv)F1-Kitl<+> | ||
| ES Cell Line Name | R1 | ||
| ES Cell Line Strain | (129X1/SvJ x 129S1/Sv)F1-Kitl<+> | ||
| Gene Symbol and Name | Adra2a, adrenergic receptor, alpha 2a | ||
| Chromosome | 19 | ||
| Gene Common Name(s) | ADRA2; ADRA2R; ADRAR; ALPHA2AAR; AW122659; Adra-2; Adra-2a; RATRG20; RG20; ZNF32; adrenergic receptor, alpha 2; alpha(2A)AR; alpha2-C10; alpha2A; alpha2A-AR; alpha2A-adrenergic receptor; expressed sequence AW122659; subtype alpha2-C10; | ||
| Molecular Note | A neomycin cassette inserted into the gene by homologous recombination resulted in a premature stop codon within the third transmembrane domain. Confirmation of the targeting event was demonstrated through Southern analysis. [MGI Ref ID J:76317] | ||
Genotyping Protocols
Adra2atm1Bkk, STD PCR, vers. 1
Helpful Links
Optimizing PCR Protocols
Altman JD; Trendelenburg AU; MacMillan L; Bernstein D; Limbird L; Starke K; Kobilka BK; Hein L. 1999. Abnormal regulation of the sympathetic nervous system in alpha2A-adrenergic receptor knockout mice. Mol Pharmacol 56(1):154-61. [PubMed: 10385696] [MGI Ref ID J:76317]
Hein L; Altman JD; Kobilka BK. 1999. Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission. Nature 402(6758):181-4. [PubMed: 10647009] [MGI Ref ID J:58591]
Adra2atm1Bkk relatedBonaventure P; Nepomuceno D; Hein L; Sutcliffe JG; Lovenberg T; Hedlund PB. 2004. Radioligand binding analysis of knockout mice reveals 5-hydroxytryptamine(7) receptor distribution and uncovers 8-hydroxy-2-(di-n-propylamino)tetralin interaction with alpha(2) adrenergic receptors. Neuroscience 124(4):901-11. [PubMed: 15026130] [MGI Ref ID J:89990]
Brede M; Nagy G; Philipp M; Sorensen JB; Lohse MJ; Hein L. 2003. Differential control of adrenal and sympathetic catecholamine release by alpha 2-adrenoceptor subtypes. Mol Endocrinol 17(8):1640-6. [PubMed: 12764077] [MGI Ref ID J:126731]
Brum PC; Kosek J; Patterson A; Bernstein D; Kobilka B. 2002. Abnormal cardiac function associated with sympathetic nervous system hyperactivity in mice. Am J Physiol Heart Circ Physiol 283(5):H1838-45. [PubMed: 12384461] [MGI Ref ID J:108048]
Bucheler MM; Hadamek K; Hein L. 2002. Two alpha(2)-adrenergic receptor subtypes, alpha(2A) and alpha(2C), inhibit transmitter release in the brain of gene-targeted mice. Neuroscience 109(4):819-26. [PubMed: 11927164] [MGI Ref ID J:126644]
Davies MF; Tsui JY; Flannery JA; Li X; DeLorey TM; Hoffman BB. 2003. Augmentation of the noradrenergic system in alpha-2 adrenergic receptor deficient mice: anatomical changes associated with enhanced fear memory. Brain Res 986(1-2):157-65. [PubMed: 12965240] [MGI Ref ID J:107779]
Fagerholm V; Gronroos T; Marjamaki P; Viljanen T; Scheinin M; Haaparanta M. 2004. Altered glucose homeostasis in alpha2A-adrenoceptor knockout mice. Eur J Pharmacol 505(1-3):243-52. [PubMed: 15556159] [MGI Ref ID J:101927]
Ferreira JC; Bacurau AV; Evangelista FS; Coelho MA; Oliveira EM; Casarini DE; Krieger JE; Brum PC. 2008. The role of local and systemic renin angiotensin system activation in a genetic model of sympathetic hyperactivity-induced heart failure in mice. Am J Physiol Regul Integr Comp Physiol 294(1):R26-32. [PubMed: 17977919] [MGI Ref ID J:130320]
Hein L; Altman JD; Kobilka BK. 1999. Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission. Nature 402(6758):181-4. [PubMed: 10647009] [MGI Ref ID J:58591]
Ihalainen JA; Tanila H. 2004. In vivo regulation of dopamine and noradrenaline release by alpha2A-adrenoceptors in the mouse nucleus accumbens. J Neurochem 91(1):49-56. [PubMed: 15379886] [MGI Ref ID J:93277]
Ihalainen JA; Tanila H. 2002. In vivo regulation of dopamine and noradrenaline release by alpha2A-adrenoceptors in the mouse prefrontal cortex. Eur J Neurosci 15(11):1789-94. [PubMed: 12081658] [MGI Ref ID J:108075]
Juhila J; Honkanen A; Sallinen J; Haapalinna A; Korpi ER; Scheinin M. 2005. alpha(2A)-Adrenoceptors regulate d-amphetamine-induced hyperactivity and behavioural sensitization in mice. Eur J Pharmacol 517(1-2):74-83. [PubMed: 15978573] [MGI Ref ID J:103792]
Knaus A; Zong X; Beetz N; Jahns R; Lohse MJ; Biel M; Hein L. 2007. Direct inhibition of cardiac hyperpolarization-activated cyclic nucleotide-gated pacemaker channels by clonidine. Circulation 115(7):872-80. [PubMed: 17261653] [MGI Ref ID J:132333]
Lahdesmaki J; Sallinen J; MacDonald E; Kobilka BK; Fagerholm V; Scheinin M. 2002. Behavioral and neurochemical characterization of alpha(2A)-adrenergic receptor knockout mice. Neuroscience 113(2):289-99. [PubMed: 12127086] [MGI Ref ID J:109288]
Lahdesmaki J; Sallinen J; MacDonald E; Sirvio J; Scheinin M. 2003. Alpha2-adrenergic drug effects on brain monoamines, locomotion, and body temperature are largely abolished in mice lacking the alpha2A-adrenoceptor subtype. Neuropharmacology 44(7):882-92. [PubMed: 12726820] [MGI Ref ID J:97152]
Lahdesmaki J; Scheinin M; Pertovaara A; Mansikka H. 2003. The alpha2A-adrenoceptor subtype is not involved in inflammatory hyperalgesia or morphine-induced antinociception. Eur J Pharmacol 468(3):183-9. [PubMed: 12754056] [MGI Ref ID J:102597]
Makaritsis KP; Johns C; Gavras I; Altman JD; Handy DE; Bresnahan MR; Gavras H. 1999. Sympathoinhibitory function of the alpha(2A)-adrenergic receptor subtype. Hypertension 34(3):403-7. [PubMed: 10489385] [MGI Ref ID J:59489]
Mansikka H; Lahdesmaki J; Scheinin M; Pertovaara A. 2004. Alpha(2A) adrenoceptors contribute to feedback inhibition of capsaicin-induced hyperalgesia. Anesthesiology 101(1):185-90. [PubMed: 15220790] [MGI Ref ID J:105328]
Moura E; Afonso J; Hein L; Vieira-Coelho MA. 2006. Alpha2-adrenoceptor subtypes involved in the regulation of catecholamine release from the adrenal medulla of mice. Br J Pharmacol 149(8):1049-58. [PubMed: 17075569] [MGI Ref ID J:135922]
Niederhoffer N; Hein L; Starke K. 2004. Modulation of the baroreceptor reflex by alpha 2A-adrenoceptors: a study in alpha 2A knockout mice. Br J Pharmacol 141(5):851-9. [PubMed: 14769782] [MGI Ref ID J:102353]
Ozdogan UK; Lahdesmaki J; Hakala K; Scheinin M. 2004. The involvement of alpha 2A-adrenoceptors in morphine analgesia, tolerance and withdrawal in mice. Eur J Pharmacol 497(2):161-71. [PubMed: 15306201] [MGI Ref ID J:101972]
Ozdogan UK; Lahdesmaki J; Mansikka H; Scheinin M. 2004. Loss of amitriptyline analgesia in alpha 2A-adrenoceptor deficient mice. Eur J Pharmacol 485(1-3):193-6. [PubMed: 14757140] [MGI Ref ID J:103497]
Ozdogan UK; Lahdesmaki J; Scheinin M. 2006. The analgesic efficacy of partial opioid agonists is increased in mice with targeted inactivation of the alpha2A-adrenoceptor gene. Eur J Pharmacol 529(1-3):105-13. [PubMed: 16325800] [MGI Ref ID J:106379]
Paris A; Mantz J; Tonner PH; Hein L; Brede M; Gressens P. 2006. The effects of dexmedetomidine on perinatal excitotoxic brain injury are mediated by the alpha2A-adrenoceptor subtype. Anesth Analg 102(2):456-61. [PubMed: 16428542] [MGI Ref ID J:134285]
Paris A; Philipp M; Tonner PH; Steinfath M; Lohse M; Scholz J; Hein L. 2003. Activation of alpha 2B-adrenoceptors mediates the cardiovascular effects of etomidate. Anesthesiology 99(4):889-95. [PubMed: 14508322] [MGI Ref ID J:106006]
Philipp M; Brede ME; Hadamek K; Gessler M; Lohse MJ; Hein L. 2002. Placental alpha(2)-adrenoceptors control vascular development at the interface between mother and embryo. Nat Genet 31(3):311-5. [PubMed: 12068299] [MGI Ref ID J:77486]
Pozgajova M; Sachs UJ; Hein L; Nieswandt B. 2006. Reduced thrombus stability in mice lacking the alpha2A-adrenergic receptor. Blood 108(2):510-4. [PubMed: 16507775] [MGI Ref ID J:135683]
Regard JB; Kataoka H; Cano DA; Camerer E; Yin L; Zheng YW; Scanlan TS; Hebrok M; Coughlin SR. 2007. Probing cell type-specific functions of Gi in vivo identifies GPCR regulators of insulin secretion. J Clin Invest 117(12):4034-43. [PubMed: 17992256] [MGI Ref ID J:130781]
Rolim NP; Medeiros A; Rosa KT; Mattos KC; Irigoyen MC; Krieger EM; Krieger JE; Negrao CE; Brum PC. 2007. Exercise training improves the net balance of cardiac Ca2+ handling protein expression in heart failure. Physiol Genomics 29(3):246-52. [PubMed: 17244791] [MGI Ref ID J:128677]
Sawamura S; Kingery WS; Davies MF; Agashe GS; Clark JD; Kobilka BK; Hashimoto T; Maze M. 2000. Antinociceptive action of nitrous oxide is mediated by stimulation of noradrenergic neurons in the brainstem and activation of [alpha]2B adrenoceptors. J Neurosci 20(24):9242-51. [PubMed: 11125002] [MGI Ref ID J:120560]
Scheibner J; Trendelenburg AU; Hein L; Starke K. 2001. Alpha2-adrenoceptors modulating neuronal serotonin release: a study in alpha2-adrenoceptor subtype-deficient mice. Br J Pharmacol 132(4):925-33. [PubMed: 11181434] [MGI Ref ID J:115396]
Scheibner J; Trendelenburg AU; Hein L; Starke K; Blandizzi C. 2002. Alpha 2-adrenoceptors in the enteric nervous system: a study in alpha 2A-adrenoceptor-deficient mice. Br J Pharmacol 135(3):697-704. [PubMed: 11834617] [MGI Ref ID J:103275]
Tan CM; Wilson MH; MacMillan LB; Kobilka BK; Limbird LE. 2002. Heterozygous alpha 2A-adrenergic receptor mice unveil unique therapeutic benefits of partial agonists. Proc Natl Acad Sci U S A 99(19):12471-6. [PubMed: 12205290] [MGI Ref ID J:127138]
Trendelenburg AU; Hein L; Gaiser EG; Starke K. 1999. Occurrence, pharmacology and function of presynaptic alpha2-autoreceptors in alpha2A/D-adrenoceptor-deficient mice Naunyn Schmiedebergs Arch Pharmacol 360(5):540-51. [PubMed: 10598793] [MGI Ref ID J:59811]
Colony Maintenance
Breeding & Husbandry This strain originated on a FVB;129 background, has been backcrossed for 5 generations to C57BL/6 and may be maintained as a homozygote. Donating Investigator reports mutant mice usually have less than 6 litters and less than 6 pups per litter.
| Pricing for USA, Canada and Mexico shipping destinations |
|
*Price(s) in US dollars ($)
Weeks of Age Price* Gender Cryorecovery Fee $1900.00 Cryopreserved Embryos Fee $1600.00
| Pricing for International shipping destinations |
|
*Price(s) in US dollars ($)
Weeks of Age Price* Gender Cryorecovery Fee $2470.00 Cryopreserved Embryos Fee $2080.00
| Standard Supply | Repository-Cryopreserved. Must Be Recovered. Please refer to pricing and supply notes for further information. |
|---|---|
| Supply Notes |
|
Purchasing Information
JAX® Mice Orders
Surgical Services
Contact Information
Orders & Technical Support
Tel: 800.422.6423 or 207.288.5845
Fax: 207.288.6150
Technical Support Email Form
For Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license prior to shipping.
| phone: | 207-288-6470 |
| fax: | 207-288-6655 |
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. THE LABORATORY EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of MICE, products or services, The Jackson Laboratory will, at its option, provide credit or replacement for the MICE or product received or the services provided.
In no event shall The Jackson Laboratory, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, products or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of The Jackson Laboratory, its agents or employees. In purchasing or receiving MICE, products or services from The Jackson Laboratory, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges The Jackson Laboratory from all such causes of action or damages, and further agrees to defend and indemnify The Jackson Laboratory from any costs or damages arising out of any third party claims.
MICE and biological materials are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to The Jackson Laboratory’s MICE, products and services. In addition, special terms and conditions of sale of certain MICE, products and services may be set forth separately in The Jackson Laboratory web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, products and services by The Jackson Laboratory, and by its licensees and distributors.
Acceptance of delivery of MICE, products or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on The Jackson Laboratory, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, products services by The Jackson Laboratory.